Caitlin M O'connor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6147580/publications.pdf

Version: 2024-02-01

1307594 1281871 16 608 7 11 citations g-index h-index papers 17 17 17 910 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. Cancer Research, 2022, 82, 721-733.	0.9	4
2	Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene, 2020, 39, 703-717.	5.9	24
3	Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis. Cancer Discovery, 2020, 10, 765-767.	9.4	1
4	Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell, 2020, 181, 688-701.e16.	28.9	107
5	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. PLoS ONE, 2020, 15, e0240169.	2.5	8
6	Abstract 2981: Biased activation of PP2A through selective heterotrimer binding and stabilization. , 2020, , .		0
7	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		O
8	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies., 2020, 15, e0240169.		0
9	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies., 2020, 15, e0240169.		O
10	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies., 2020, 15, e0240169.		0
11	Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45). Journal of Biological Chemistry, 2019, 294, 17043-17059.	3.4	11
12	The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. Cancer Research, 2019, 79, 4242-4257.	0.9	37
13	Protein phosphatase 2A AÎ \pm regulates AÎ 2 protein expression and stability. Journal of Biological Chemistry, 2019, 294, 5923-5934.	3.4	7
14	Therapeutic targeting of PP2A. International Journal of Biochemistry and Cell Biology, 2018, 96, 182-193.	2.8	138
15	PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine, 2018, 10, .	12.4	116
16	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. Journal of Clinical Investigation, 2017, 127, 2081-2090.	8.2	155